There have not been sufficient numbers of geriatric patients in controlled clinical studies with AVEED to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. Safety and effectiveness of AVEED in pediatric patients less than 18 years old have not been established. Testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. In the 84-week clinical trial, 7 patients (4.6%) discontinued treatment because of adverse reactions. Table 1 presents adverse reactions reported by ≥1% of patients in the 84-week clinical study. Following each injection of AVEED, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions or anaphylaxis see WARNINGS AND PRECAUTIONS. AVEED should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of POME and anaphylaxis.. Patients were selected using a similar criterion to the above study; 27 were given 80mg of testosterone undecanoate twice a day, while six were given placebos.|Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. In the 84-week clinical trial of AVEED, 1 patient experienced a mild coughing fit lasting 10 minutes after his third injection, which was retrospectively attributed to POME. Adverse events attributable to POME and anaphylaxis were reported in a small number of patients in controlled clinical trials. Several of these clinical trials incorporated additional doses upon initiation of therapy (eg, loading doses). AVEED was evaluated in an 84-week clinical study using a dose regimen of 750 mg (3 mL) at initiation, at 4 weeks, and every 10 weeks thereafter in 153 hypogonadal men. If there is bleeding at the site of injection, apply a bandage. Immediately upon removal of the needle from the muscle, apply gentle pressure with a sterile pad to the injection site.|A total of 117 out of 130 hypogonadal men completed study procedures through Week 24 and were included in the evaluation of testosterone pharmacokinetics after the third AVEED injection. Eligible patients weighed at least 65 kg, were 18 years of age and older (mean age 54.2 years), and had a morning serum total testosterone concentration 2. Higher serum testosterone average concentrations (579 ± 101 ng/dL and 567± 155ng/dL) were observed in patients with BMIs 2 and 26 to 30 kg/m2, respectively. A higher serum testosterone average concentration (568 ± 139 ng/dL) was observed in 57 patients weighing 65 to 100 kg. Analysis of serum testosterone concentrations from 117 hypogonadal men in the 84-week clinical study of AVEED indicated that serum testosterone concentrations achieved were inversely correlated with the patient’s body weight.|In addition to its medical use, testosterone undecanoate is used to improve physique and performance. However, it has advantages over other testosterone esters in that it can be taken by mouth and in that it has a far longer duration when given by injection. Along with testosterone enanthate, testosterone cypionate, and testosterone propionate, testosterone undecanoate is one of the most widely used testosterone esters. It has strong androgenic effects and moderate anabolic effects, which make it useful for producing masculinization and suitable for androgen replacement therapy. Food and Drug Administration, there are no true quantifiable benefits of taking testosterone supplements.|Cleavage of the undecanoic acid side chain of AVEED by tissue esterases releases testosterone. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has 2 main etiologies. No studies were conducted in patients with hepatic impairment. No studies were conducted in patients with renal impairment.|Structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen. Structural impairments observed in females included increased anogenital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. In developmental studies conducted in rats, rabbits, pigs, sheep and rhesus monkeys, pregnant animals received intramuscular injection of testosterone during the period of organogenesis. In animal development studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring.|In November 2003, Nebido, an injectable testosterone undecanoate formulation made by Schering AG, received its initial European approval in Finland. Testosterone undecanoate is metabolized partially in the intestinal wall into 5-alpha-dihydrotestosterone undecanoate (DHTU). It is absorbed through the lymphatic system (90-100%) and peak serum levels are reached after about 3-5 hours. This bioavailability is increased with food, especially foods containing fat, thus it is typically recommended to be taken with a meal.} The treatment of hypogonadal men with testosterone products may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung diseases. Long-term therapy with intramuscular testosterone enanthate, which elevates blood levels for prolonged periods, has produced multiple hepatic adenomas. Following each injection of AVEED, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions and anaphylaxis. Serious POME reactions, involving cough, urge to cough, dyspnea, hyperhidrosis, throat tightening, chest pain, dizziness, and syncope, have been reported to occur during or immediately after the injection of intramuscular testosterone undecanoate 1000 mg (4 mL). The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring, particularly in patients with cardiac, renal or hepatic disease. During a review that involved adjudication of all cases meeting specific criteria, 9 POME events in 8 patients and 2 events of anaphylaxis among 3,556 patients treated with intramuscular testosterone undecanoate in 18 clinical trials were judged to have occurred. During the 84-week clinical trial, the average serum PSA increased from 1.0 ± 0.8 ng/mL at baseline to 1.5 ± 1.3 ng/mL at the end of study. The patient's symptoms subsided once his father's treatment had been changed to a buccal modality . The patient had developed precocious puberty due to the transfer of testosterone from the patient's father, who had been undergoing treatment for hypogonadism using a topical gel. Wang et al. found that skin irritation was reported in 5.5% of subjects treated with testosterone gel and 66% of subjects in the testosterone patch group . Due to an increased incidence of adverse cardiovascular events compared to a placebo group, a Testosterone in Older Men with Mobility Limitations (TOM) trial (a National Institute of Aging randomized trial) was halted early by the Data Safety and Monitoring Committee. Other side effects include increased hematocrit, which can require venipuncture in order to treat, and exacerbation of sleep apnea. Breast cancer is said by some sources to be an absolute contraindication of testosterone therapy, but androgens including testosterone have also actually been used to treat breast cancer. The reasons cited were limited efficacy (about one additional sexually satisfying event per month), concerns about safety and potential adverse effects with long-term therapy, and concerns about inappropriate off-label use. Steady-state serum testosterone concentration was achieved with the third injection of AVEED at 14 weeks. Following intramuscular injection of 750 mg of AVEED, serum testosterone concentrations reach a maximum after a median of 7 days (range 4 to 42 days) then slowly decline (Figure 3). Testosterone treatment at doses that were comparable to those used for testosterone replacement therapy resulted in structural impairments in both female and male offspring. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Changes in serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy. With large doses of exogenous androgens, including AVEED, spermatogenesis may be suppressed through feedback inhibition of pituitary FSH which could possibly lead to adverse effects on semen parameters including sperm count. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events. In February 2025, the US Food and Drug Administration (FDA) specified label changes for products containing testosterone. Another approach being investigated is the detection of the administered form of testosterone, usually an ester, in hair. These include the testosterone/epitestosterone ratio (normally less than 6), the testosterone/luteinizing hormone ratio and the carbon-13/carbon-12 ratio (pharmaceutical testosterone contains less carbon-13 than endogenous testosterone). A number of methods for detecting testosterone use by athletes have been employed, most based on a urine test. This has proven contentious, with the Court of Arbitration for Sport suspending the IAAF policy due to insufficient evidence of a link between high androgen levels and improved athletic performance. Alternatively, testosterone products for women are available from compounding pharmacies in the United States, although such products are unregulated and manufacturing quality is not ensured. There are approved testosterone products for women in Australia, where it is considered a drug of dependence, medicines that are subject to misuse and trafficking, and some European countries.
Download App
